Condition: Colorectal Cancer · Pancreatic Cancer · Melanoma · Sponsor: ViroMissile, Inc.
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
This description comes directly from the study's public registry record.
Clinical Development · 858-886-7718 · clinicaltrials@viromissile.com
Always discuss trial participation with your own doctor first.
| Washington University School of Medicine | St Louis, Missouri, United States | Not Yet Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| South Texas Accelerated Research Therapeutics | San Antonio, Texas, United States | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06910657